William Blair Issues Optimistic Estimate for TWST Earnings

Twist Bioscience Co. (NASDAQ:TWST) – Equities research analysts at William Blair lifted their Q1 2025 earnings per share estimates for shares of Twist Bioscience in a research report issued on Monday, November 18th. William Blair analyst M. Larew now anticipates that the company will post earnings per share of ($0.58) for the quarter, up from their prior forecast of ($0.72). The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.56) per share. William Blair also issued estimates for Twist Bioscience’s Q2 2025 earnings at ($0.57) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($2.11) EPS.

Several other research firms have also weighed in on TWST. Robert W. Baird upped their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday. Evercore ISI increased their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. Barclays lowered their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday. Finally, Leerink Partners boosted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $51.78.

Twist Bioscience Trading Up 1.4 %

Shares of NASDAQ TWST opened at $42.23 on Thursday. Twist Bioscience has a one year low of $23.07 and a one year high of $60.90. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -11.81 and a beta of 1.78. The business has a fifty day simple moving average of $43.88 and a 200 day simple moving average of $46.12.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TWST. Geode Capital Management LLC grew its holdings in shares of Twist Bioscience by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after purchasing an additional 26,145 shares during the last quarter. Barclays PLC lifted its stake in shares of Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after acquiring an additional 104,420 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Twist Bioscience by 36.7% during the 3rd quarter. XTX Topco Ltd now owns 15,518 shares of the company’s stock valued at $701,000 after acquiring an additional 4,169 shares in the last quarter. Wellington Management Group LLP grew its position in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after acquiring an additional 521,272 shares during the last quarter. Finally, State Street Corp increased its holdings in Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares in the last quarter.

Insider Activity at Twist Bioscience

In other news, CEO Emily M. Leproust sold 14,334 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the completion of the sale, the chief executive officer now owns 589,552 shares in the company, valued at approximately $26,294,019.20. This trade represents a 2.37 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Adam Laponis sold 856 shares of the stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total value of $35,789.36. Following the transaction, the chief financial officer now owns 73,397 shares in the company, valued at approximately $3,068,728.57. This trade represents a 1.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,118 shares of company stock worth $4,391,151 in the last ninety days. Company insiders own 3.92% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.